The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).
 
Herve Tilly
Honoraria - Celgene; Roche/Genentech; SERVIER
Consulting or Advisory Role - AstraZeneca; Karyopharm Therapeutics; Roche
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Roche
 
Christopher Flowers
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Celgene; Denovo Biopharma; Gilead Sciences; Karyopharm Therapeutics; OptumRx; Pharmacyclics/Janssen; Seagen; Spectrum Pharmaceuticals
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immune Design (Inst); Infinity Pharmaceuticals (Inst); Janssen Oncology (Inst); Onyx (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; Genentech/Roche; Gilead Sciences
 
Jonathan W. Friedberg
Consulting or Advisory Role - Bayer
Research Funding - Kite, a Gilead company (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Roche
 
Charles Herbaux
Honoraria - Bristol-Myers Squibb; Janssen; Roche
 
Franck Morschhauser
Honoraria - Bristol-Myers Squibb; Genentech; Janssen; Roche
Consulting or Advisory Role - Celgene; Gilead Sciences; Roche
 
Laurie Helen Sehn
Consulting or Advisory Role - Abbvie; Amgen; Celgene; Gilead Sciences; Janssen; Lundbeck; Roche/Genentech; Seagen; TG Therapeutics
 
Jeff Porter Sharman
Leadership - US Oncology
Consulting or Advisory Role - Celgene; Genentech; Gilead Sciences; Pharmacyclics; TG Therapeutics
Speakers' Bureau - Gilead Sciences
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst)
Expert Testimony - Gilead Sciences
 
Marek Trněný
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Incyte; Janssen; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Incyte; Janssen; Roche; Takeda
Travel, Accommodations, Expenses - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Incyte; janssen; Roche; Takeda
 
Lijia Wang
Employment - Genentech/Roche
 
Calvin Lee
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
 
Gilles A. Salles
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Gilead Sciences; Gilead Sciences; Janssen; Novartis; Roche/Genentech; SERVIER
Consulting or Advisory Role - Acerta Pharma; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Kite, a Gilead company; Merck; Novartis; Novimmune; Pfizer; Roche/Genentech; SERVIER
Research Funding - Celgene; Gilead Sciences; Merck; Roche/Genentech; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech; Sanofi